ImmunoCellular establishes agreement with Novella Clinical
ImmunoCellular announced an agreement with Novella Clinical to conduct the phase 3 registration trial of ICT-107 in patients with newly diagnosed glioblastoma. The ICT-107 phase 3 trial will include approximately 120 clinical sites in the US, Europe and Canada. July 06, 2015